Pepinemab (VX15/2503) is a humanized monoclonal IgG4 antibody that binds and blocks the signaling activity of SEMA4D, a signaling molecule that regulates the migration and activation of immune and inflammatory cells at sites of injury or damage in the brain and in tumors.
Vaccinex is evaluating pepinemab in clinical trials for people living with Huntington’s and Alzheimer’s disease, and is exploring the potential to treat other neurological disorders.
Vaccinex is evaluating pepinemab in clinical trials of patients with solid tumors such as breast cancer, melanoma, non-small cell lung cancer and head and neck cancer.
Our Technology
Vaccinex has developed a fusion protein technology to enable the direct incorporation of multi-pass membrane proteins such as GPCRs and ion channels into the membrane of two antigenically distinct BSL1 poxviruses: MVA and FPV.
Antigen expressing virus can be readily purified and used for antibody selection employing either in vitro display or in vivo immunization methods.
Get in touch with our team.
Let us know how we can help with your research.
Email Addresses
General inquiries:
Info@vaccinex.com
ActivMab Discovery Services: Activmab@vaccinex.com
Vaccinex, Inc.
1895 Mt. Hope Avenue
Rochester, NY 14620
Ph: 585-271-2700
Fx: 585-271-2765